ALSO Holding AG (SWX:ALSN)
Switzerland · Delayed Price · Currency is CHF 246.50
-6.00 (-2.38%)
Jul 31, 2025, 5:31 PM CET
Ligand Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 11,153 | 9,506 | 9,960 | 11,553 | 11,595 | 11,898 | Upgrade | |
Revenue Growth (YoY) | 18.52% | -4.56% | -13.79% | -0.36% | -2.55% | 11.28% | Upgrade |
Cost of Revenue | 10,384 | 8,832 | 9,284 | 10,857 | 10,927 | 11,274 | Upgrade |
Gross Profit | 768.75 | 673.35 | 675.24 | 695.98 | 668.03 | 623.95 | Upgrade |
Selling, General & Admin | 310.65 | 270.04 | 261.33 | 267.58 | 254.07 | 239.2 | Upgrade |
Other Operating Expenses | 200.27 | 177.06 | 158.66 | 164.23 | 154.47 | 152.99 | Upgrade |
Operating Expenses | 564.59 | 488.95 | 464.59 | 474.98 | 448.21 | 434.39 | Upgrade |
Operating Income | 204.16 | 184.4 | 210.64 | 221 | 219.82 | 189.56 | Upgrade |
Interest Expense | -49.72 | -33.69 | -35.06 | -28.48 | -17.56 | -18.16 | Upgrade |
Interest & Investment Income | 15.07 | 15.07 | 11.27 | 1.45 | 0.61 | 0.7 | Upgrade |
Currency Exchange Gain (Loss) | -0.21 | -0.21 | - | -0.05 | 0.04 | -0.19 | Upgrade |
Other Non Operating Income (Expenses) | -5.97 | -5.97 | -4.63 | -3.95 | -3.45 | -4.29 | Upgrade |
EBT Excluding Unusual Items | 163.33 | 159.6 | 182.23 | 189.96 | 199.46 | 167.62 | Upgrade |
Merger & Restructuring Charges | -3.1 | -3.1 | -8 | -3.8 | -2.3 | -4 | Upgrade |
Gain (Loss) on Sale of Assets | 11.05 | 11.05 | - | 19.71 | 2.13 | -0.27 | Upgrade |
Other Unusual Items | - | - | 0.3 | 2.07 | 1.8 | 4.37 | Upgrade |
Pretax Income | 171.28 | 167.55 | 174.52 | 207.94 | 201.09 | 167.72 | Upgrade |
Income Tax Expense | 54.62 | 52.3 | 50.42 | 55.57 | 46.89 | 37.75 | Upgrade |
Earnings From Continuing Operations | 116.66 | 115.25 | 124.11 | 152.37 | 154.2 | 129.97 | Upgrade |
Minority Interest in Earnings | -0.3 | -0.2 | -0.44 | -0.32 | -0.19 | 0.09 | Upgrade |
Net Income | 116.36 | 115.05 | 123.66 | 152.05 | 154 | 130.06 | Upgrade |
Net Income to Common | 116.36 | 115.05 | 123.66 | 152.05 | 154 | 130.06 | Upgrade |
Net Income Growth | 3.16% | -6.97% | -18.67% | -1.27% | 18.41% | 30.07% | Upgrade |
Shares Outstanding (Basic) | 12 | 12 | 12 | 13 | 13 | 13 | Upgrade |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 13 | 13 | 13 | Upgrade |
Shares Change (YoY) | 2.22% | -0.23% | -3.78% | -0.46% | - | -0.00% | Upgrade |
EPS (Basic) | 9.32 | 9.39 | 10.07 | 11.91 | 12.01 | 10.14 | Upgrade |
EPS (Diluted) | 9.32 | 9.39 | 10.07 | 11.91 | 12.01 | 10.14 | Upgrade |
EPS Growth | 0.93% | -6.75% | -15.48% | -0.81% | 18.41% | 30.07% | Upgrade |
Free Cash Flow | -40.79 | 310.58 | 376 | 80.61 | 285.04 | 239.35 | Upgrade |
Free Cash Flow Per Share | -3.27 | 25.35 | 30.62 | 6.32 | 22.23 | 18.67 | Upgrade |
Dividend Per Share | 5.436 | 5.436 | 5.157 | 4.655 | 4.148 | 3.465 | Upgrade |
Dividend Growth | 5.41% | 5.41% | 10.79% | 12.23% | 19.70% | 15.87% | Upgrade |
Gross Margin | 6.89% | 7.08% | 6.78% | 6.02% | 5.76% | 5.24% | Upgrade |
Operating Margin | 1.83% | 1.94% | 2.11% | 1.91% | 1.90% | 1.59% | Upgrade |
Profit Margin | 1.04% | 1.21% | 1.24% | 1.32% | 1.33% | 1.09% | Upgrade |
Free Cash Flow Margin | -0.37% | 3.27% | 3.77% | 0.70% | 2.46% | 2.01% | Upgrade |
EBITDA | 234.89 | 203.3 | 228.16 | 238.52 | 236.83 | 208.24 | Upgrade |
EBITDA Margin | 2.11% | 2.14% | 2.29% | 2.06% | 2.04% | 1.75% | Upgrade |
D&A For EBITDA | 30.73 | 18.9 | 17.52 | 17.52 | 17.01 | 18.67 | Upgrade |
EBIT | 204.16 | 184.4 | 210.64 | 221 | 219.82 | 189.56 | Upgrade |
EBIT Margin | 1.83% | 1.94% | 2.11% | 1.91% | 1.90% | 1.59% | Upgrade |
Effective Tax Rate | 31.89% | 31.21% | 28.89% | 26.73% | 23.32% | 22.51% | Upgrade |
Updated Feb 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.